The Johns Hopkins University

Champions Biotechnology, Inc.

Manuel Medina Hidalgo

Antonio Jimeno

Bert Vogelstein

Kenneth W Kinzler

Victor E Velculescu

Ralph Hruban

Sian Jones

D Williams Parsons

Scott E Kern

Michael Goggins

Saeed R Khan

James R Eshleman

Alison Klein

Gurulinsappa Hallur

The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction of stabilization of at least one sign or symptom of cancer.

ON01910.Na enhances chemotherapeutic agent activity in drug-resistant tumors

The present invention provides a method for detecting mutations in the PALB2 gene in pancreatic cancer patients and in individuals having a family history of pancreatic cancer. Methods are also provided for diagnosing a predisposition to pancreatic cancer, for predicting a patient's response to pancreatic cancer therapies, and for treating pancreatic cancer, based on presence of a PALB2 mutation or abberant PALB2 gene expression in a patient.

Diagnostic method using PALB2

The invention includes compositions and methods of treatment of cancers susceptible to treatment with nucleotide analog chemotherapeutic agent, including cancers in which nucleotide analog resistant tumors have developed, including identifying a subject having cancer susceptible to treatment with a nucleotide analog chemotherapeutic agent and a mitotic disruptor/polo-like kinase (Plk) pathway inhibitor to a subject; and monitoring the subject for a reduction or stabilization of at least one sign or symptom of cancer.

A novel series of BPU analogues were synthesized and evaluated for antitumor activity. In particular, BPU sulfur analogues 6and 7were shown to possess up to 10-fold increased potency, when compared to compound 1, against cancer cell lines. 6was more effective than compound 1 in causing apoptosis of MCF-7 cells. When compared to other drugs with a similar mechanism of action, 6retained significant ability to inhibit tubulin assembly, with an ICof 2.1 &#x3bc;M.

Synthesis of novel tubulin polymerization inhibitors: benzoylphenylurea (BPU) sulfur analogs

Growing community of inventors

Baltimore, MD, United States of America

Manuel Medina Hidalgo